Intrasense, a French specialist in medical imaging and artificial intelligence solutions, today announces its half-year results for the six months ended 30 June 2026. These financial statements were approved by the Board of Directors on 28 September 2026.

Intrasense, a French expert in medical imaging, announces the launch of an end-of-life
process (“End of Life”) for its solutions Myrian®, Liflow®, DUOnco™ Liver and DUOnco™ Bone, as well as the
launch of a new restructuring plan intended to adjust the size of its teams to its new scope of activity.

Intrasense, French specialist in medical imaging solutions, announces that its new oncology follow-up solution, DUOnco™ Unity, has obtained CE marking under the European Medical Device Regulation (MDR 2017/745).

Intrasense, French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, announces the termination of the proposed sale of the technological assets, intellectual property, customer and partner contracts, and the teams dedicated to the Myrian business to EDL.

Intrasense, a French expert in AI-enhanced medical imaging solutions that facilitate diagnosis, decision-making, and treatment monitoring, announces the postponement of the release of its 2026 half-year results and financial report, originally scheduled for September 15, 2026.